- The Clinical Immunohistochemistry group is responsible for supporting a book of work comprised of several dozen individual projects in the Oncology, Immuno-Oncology and Immunoscience portfolios. The group primarily focuses on creating, validating and implementing IHC-based assays in the early clinical translational research space to generate critical data which support 1) mechanism of action hypotheses, 2) pharmacodynamic evaluations, and 3) identification of novel biomarkers related to clinical response. The team is also responsible for delivering on all outsourced clinical samples needing IHC endpoints including vendor management and quality oversight. Members of the team are also deeply engaged in new technology identification and evaluations, including multiplexed IHC, digital image analysis, deep learning and other emerging technologies critical to the continued scientific leadership of BMS. The group works closely with the diagnostics team transfer assay methods to diagnostic companies for companion/complementary diagnostic development. Members of this team work on various projects in concert with multiple groups including oncology development teams, translational biology, biomarkers and pharmacodiagnostics. Additional key responsibilities include transferring and overseeing the execution of IHC work at external partners, and collaborating to provide technical expertise and analytical guidance for critical academic partnerships with BMS. Additionally, the team is responsible for keeping current with advanced technologies related to tissue-based assays, including Cytof based multiplexing, laser microdissection, spatial transcriptomics, advanced digital pathology, image analysis and deep learning.
We are seeking an accomplished scientific and organizational leader to lead a talented group of scientists in developing fit for purpose clinical trial assays to support the early and late clinical development programs. He/She will have strong track record of success in tissue-based assays and research pathology. This person will have strong working knowledge of pathology and will need to work closely and collaboratively with a team of translational pathologists. Preference will be given to candidates who have a deep familiarity with managing clinical biomarker laboratories as well as experience developing in vitro diagnostic assays as companion/complementary diagnostics and/or have deep experience with pharma services laboratories. .
• This position requires a PhD and/or MD, or their foreign equivalents, and demonstration of scholarly productivity in a relevant field of biomedical research.
• Preference will be given to individuals with hands-on experience or experience supervising others in applying advanced digital microscopy and software methods for quantitative assessment of IHC results.
• Qualified candidates must have at least 8 years work experience (clinical, academic and/or biopharma). Preference will be given to individuals with previous experience in the field of oncology and immunology biomarkers.
• Prior experience with clinical studies and diagnostic development is a plus.
• Successful candidate will be a highly motivated and collaborative individual with experience of managing people and the ability to multitask and drive team achievement while working across multiple disciplines in a complex matrix organization.
• Excellent written and verbal communication skills and the ability to clearly communicate scientific objectives and project results are required.
• Strong understanding and track record of developing and implementing strategic initiatives that improve scientific and/or operational activities.
• Demonstrated ability to grow and foster career development of direct reports as well as track record of building high performing teams.
• Familiarity with the techniques common to translational research including flow cytometry, genomics, proteomics and importantly, data analysis.
• Ability to interact well with senior managers and develop and articulate a strategy for translational research.
• Understanding of good clinical laboratory practices is preferred
• Strong understanding with CAP/CLIA regulations a plus